EGFR and neoplasm: In cells expressing high MET and EGFR, LY2875358 is superior in internalizing/degrading EGFR (wild-type and mutant forms) over a combination of emibetuzumab and cetuximab (an approved EGFR inhibitor [16]); similarly, in comparison with the combination of individual antibodies, LY3164530 leads to greater anti-tumor activity in in vivo models and has the ability to better overcome HGF-mediated resistance to erlotinib, gefitinib, lapatanib, or vemurafenib in in vitro assays [17].